PressSeptember 16, 2022 Innovation1 Biotech Appoints Frederick E. Pierce, II to its Board of Directors
PressSeptember 15, 2022 Blackhawk’s MindBio Therapeutics Announces Reveal Date for Presentation of Phase 1 Clinical Trial Data
PressSeptember 15, 2022 HealingMaps Announces $1 Million in Seed Funding to Power Growth in Psychedelic Therapy Industry
PressSeptember 15, 2022 Silo Pharma Announces Implementation of 1-for-50 Reverse Stock Split in Preparation for Planned Uplisting to Nasdaq
LifestyleSeptember 15, 2022 Psychedelic Analogues Solve The Problems Of Limiting Psychedelic Treatment Model
PressSeptember 15, 2022 Mydecine Innovations Group Files Prospectus Supplement and Announces Closing Under Share Subscription Agreement
PressSeptember 14, 2022 Sunstone Therapies Collaborates with MAPS to Conduct Clinical Trial of MDMA-Assisted Therapy for PTSD
PressSeptember 14, 2022 Health Canada Provides a No Objection Letter to ATMA’s N500 Phase II Clinical Trial Application, Paving The Way For The Largest Psilocybin Trial To Date
PressSeptember 14, 2022 Mindset Pharma Receives Scientific Advice from UK Regulator Facilitating Advancement of Phase 1 First-In-Human Clinical Trial Plan for Its Lead Clinical Candidate, MSP-1014
PressSeptember 13, 2022 Nature Biotechnology Selects Delix Therapeutics as a Leading Biotech Start-Up
BlogSeptember 13, 2022 What Can Psychedelics Learn From the Cannabis Industry?: Mindshifting Moments #10
PressSeptember 13, 2022 Numinus provides update on acquisition integration and announces new client financing options
PressSeptember 13, 2022 Seelos Therapeutics Announces the Participation of Acadia Healthcare in the Registration Directed Study of SLS-002 (Intranasal Racemic Ketamine) for Acute Suicidal Ideation and Behavior in Patients with Major Depressive Disorder
